TW201427720A - 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法 - Google Patents

含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法 Download PDF

Info

Publication number
TW201427720A
TW201427720A TW102136760A TW102136760A TW201427720A TW 201427720 A TW201427720 A TW 201427720A TW 102136760 A TW102136760 A TW 102136760A TW 102136760 A TW102136760 A TW 102136760A TW 201427720 A TW201427720 A TW 201427720A
Authority
TW
Taiwan
Prior art keywords
angiotensin
antagonist
calcium
receptor antagonist
production method
Prior art date
Application number
TW102136760A
Other languages
English (en)
Chinese (zh)
Inventor
Ichirou Hara
Yukiko Tanaka
Hiroyuki Higuchi
Akiko Teramoto
Tomoya Onoshita
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of TW201427720A publication Critical patent/TW201427720A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102136760A 2012-10-12 2013-10-11 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法 TW201427720A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012226984 2012-10-12

Publications (1)

Publication Number Publication Date
TW201427720A true TW201427720A (zh) 2014-07-16

Family

ID=50477509

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102136760A TW201427720A (zh) 2012-10-12 2013-10-11 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法

Country Status (4)

Country Link
JP (2) JP5790965B2 (ja)
KR (2) KR101931489B1 (ja)
TW (1) TW201427720A (ja)
WO (1) WO2014058047A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5854371B2 (ja) * 2012-10-12 2016-02-09 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
JP6843498B2 (ja) * 2015-10-14 2021-03-17 Ｅａファーマ株式会社 錠剤、固体分散体顆粒及びその製造方法
JP6967833B2 (ja) * 2015-11-30 2021-11-17 大原薬品工業株式会社 医薬品包装箱を利用した、配合錠の両面印字情報の提供方法
JP2017210435A (ja) * 2016-05-25 2017-11-30 ダイト株式会社 イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法
KR101769293B1 (ko) * 2016-09-30 2017-08-30 주식회사 종근당 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
JP3415291B2 (ja) * 1994-09-27 2003-06-09 味の素ファルマ株式会社 重炭酸透析用剤
RU2245136C2 (ru) * 2001-07-27 2005-01-27 Яманоути Фармасьютикал Ко., ЛТД Композиция, включающая тонкодисперсные частицы с замедленным высвобождением для быстроразлагающихся в щечной полости таблеток, и способ ее получения
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
AR061627A1 (es) * 2006-06-27 2008-09-10 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
WO2008016171A1 (fr) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Agent prophylactique/thérapeutique destiné à un dysfonctionnement rénal
JP2008044871A (ja) 2006-08-11 2008-02-28 Ajinomoto Co Inc 心血管疾患予防・治療剤
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
WO2008120724A1 (ja) * 2007-03-30 2008-10-09 Ajinomoto Co., Inc. 固体分散体製剤
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
BRPI1009367A2 (pt) * 2009-05-27 2016-03-08 Dasan Medichem Co Ltd tablete de camada múltipla

Also Published As

Publication number Publication date
JP2015003915A (ja) 2015-01-08
JP5790965B2 (ja) 2015-10-07
KR20160105543A (ko) 2016-09-06
KR101931489B1 (ko) 2018-12-24
WO2014058047A1 (ja) 2014-04-17
KR20150065887A (ko) 2015-06-15
KR101778050B1 (ko) 2017-09-13
JP6302802B2 (ja) 2018-03-28
JPWO2014058047A1 (ja) 2016-09-05

Similar Documents

Publication Publication Date Title
CA3101822C (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof
AU2005271192B2 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2532450C (en) Chlorthalidone combinations
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
AU2007297333A1 (en) Solid dosage form of olmesartan medoxomil and amlodipine
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
CA2644179C (en) Novel pharmaceutical composition comprising a disintegration matrix
TWI586353B (zh) Pharmaceutical preparations containing calcium antagonists and angiotensin II receptor antagonists
CZ293345B6 (cs) Dihydrát monomethansulfonatu kyseliny (E)-alfa-[2-n-butyl-1-[(4-karboxyfenyl)methyl]-1H-imidazol-5-yl]methylen-2-thiofenpropionové
TW201427720A (zh) 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法
CA2764172A1 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2701689B1 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
TWI414310B (zh) 溶出性改善之醫藥品組成物
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
EP1560568A1 (en) Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate
WO2011141783A2 (en) Pharmaceutical composition comprising irbesartan
MX2014000106A (es) Composiciones farmaceuticas que comprenden una combinacion de telmisartan e hidroclorotiazida y procedimiento para la preparacion de las mismas.